Spark Therapeutics (Germany) Profile

EUR 0.000001  0.00%

Spark Therapeutics Summary

Spark Therapeutics (272) is traded on Frankfurt Stock Exchange in Germany. It is located in 3737 Market Street and employs 315 people. The company currently falls under 'Mid-Cap' category with current market capitalization of 2.46 B. Spark Therapeutics has 36.93 M outstanding shares. SPARK THERAPEUTICS has accumulated about 520.17 M in cash with (154.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.98.
Check Spark Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 66.39HorizonTargetOdds Above 66.39
78.76%30 days 66.39 21.19%
Based on normal probability distribution, the odds of Spark Therapeutics to move above current price in 30 days from now is about 21.19% (This Spark Therapeutics probability density function shows the probability of Spark Therapeutics Stock to fall within a particular range of prices over 30 days) .

Spark Therapeutics Risk Profiles

Key Fundamentals

Spark Therapeutics Against Markets

Current Ratings

Spark Therapeutics 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Spark Therapeutics are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania. Spark Therapeutics operates under Biotechnology classification in Germany and traded on Frankfurt Stock Exchange. It employs 315 people. more
NameSpark Therapeutics
CEO, Co-Founder, DirectorJeffrey MarrazzoView All
Macroaxis Advice
InstrumentGermany Stock View All
Business Address3737 Market Street
ExchangeFrankfurt Stock Exchange
Contact Number215 220 9300
CurrencyEUR - Euro

Diversify with Spark Therapeutics

Build Optimal Portfolios
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Spark Therapeutics to your portfolio


Spark Therapeutics Corporate Directors
Robert Perez Director
Lars Ekman Independent Director, Ph.D
Lorris Betz Director
Check also Trending Equities. Please also try Equity Valuation module to check real value of public entities based on technical and fundamental data.